Emulate, Inc.
27 Drydock Ave
5th Floor
Boston
Massachusetts
02210
United States
Website: https://www.emulatebio.com/
55 articles about Emulate, Inc.
-
EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG
11/14/2023
EMulate Therapeutics, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia.
-
Emulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics Markets
6/26/2023
Emulate, Inc., the leading provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.
-
Emulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
3/2/2023
Emulate, Inc., a leading provider of next-generation in vitro models, announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
-
Emulate Publishes Landmark Study Validating Organ-on-a-Chip Technology for Predictive Toxicology in Preclinical Development
12/6/2022
Emulate, Inc. today announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%.
-
EMulate Therapeutics Forms Technology Advisory Committee to Promote Growth and Innovation
10/3/2022
EMulate Therapeutics today announced the formation of a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation.
-
Emulate Announces New Gene Therapy Application Enabling Accelerated Development of Treatments for Genetic Diseases with Organ-on-a-Chip Technology
9/19/2022
Emulate, Inc. , a leading provider of next-generation in vitro models, today announced the launch of its new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks, not months, as with animal models.
-
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
-
Emulate Announces Launch of Immune Cell Recruitment Application for the Colon Intestine-Chip to Aid in the Study of Inflammatory Bowel Disease
5/9/2022
Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.
-
Emulate Announces Promotion of Dr. Lorna Ewart to Chief Scientific Officer
2/3/2022
Emulate, Inc., a leading provider of next-generation in vitro models, today announced the promotion of Lorna Ewart, PhD, to Chief Scientific Officer.
-
Emulate Brain-Chip to Study the Effects of Microgravity on Human Brain Physiology at the International Space Station
12/21/2021
Emulate, Inc., a leading provider of next-generation in vitro models, today announced that the Brain-Chip is being sent to the International Space Station U.S. National Laboratory (ISS National Lab) to study the effects of microgravity on human brain physiology as part of the Tissue-Chips in Space initiative sponsored by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and the International Space Station National Lab (ISS-NL).
-
EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries
11/17/2021
EMulate Therapeutics Has Incorporated Two Wholly Owned Subsidiaries to Deploy Its Platform Technology for the Treatment of Pain Management and Numerous Mental Health Conditions.
-
Emulate Introduces the Second-Generation Zoë® Culture Module for Replicating Complex Human Biology and Drug Effect
11/15/2021
Emulate Introduces the Second-Generation Zoë ® Culture Module for Replicating Complex Human Biology and Drug Effect
-
Emulate Appoints Scott D. Kantor as Chief Financial Officer
6/22/2021
Emulate Inc., a leading provider of next-generation in vitro models, today announced the appointment of Scott D. Kantor as Chief Financial Officer.
-
EMulate Therapeutics to Participate in the Venture Summit/Virtual Connect West on March 17 at 12pm PST
3/11/2021
EMulate Therapeutics Inc, a clinical-stage therapeutic device company, announced that management will participate in the Venture Summit...
-
Emulate Names Donald Ingber to Board of Directors
2/18/2021
Technology Visionary will Offer Strategic Insight to Guide Ongoing Research & Development of Market Leading Organ-on-a-Chip Technology
-
Emulate Announces Organ-on-a-Chip Application and Services Roadmap
1/8/2021
Expanded In Vitro Modeling Tools Will Enable Researchers to Better Understand the Effects of Advanced Biologics and Gene Therapies
-
Emulate Announces Lung-Chip Technology Used by U.S. Army to Study Effects of COVID-19
12/8/2020
Emulate, Inc., a leading provider of advanced in vitro models, today announced that its Alveolus Lung-Chip is being used by the U.S. Army to understand how the SARS-CoV-2 virus interacts with lung cells.
-
Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2
10/29/2020
Agency-wide CRADA agreement also includes studies with Brain-Chip in Alzheimer’s disease, Intestine-Chip in microbiome health, and Liver-Chip in individualized toxicity responses
-
Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman
3/19/2020
Company Builds Leadership Team for Next Stage of Growth with Expanded Commercialization of Organs-on-Chips Product Suite
-
Emulate Achieves 150 User Installations of Zoë® Instrument as a Lab-Ready Organs-on-Chips Platform, Along With 3 Commercially Available Chips for Liver, Kidney, and Intestine
3/19/2020
Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide